AR108552A1 - Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos - Google Patents
Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticosInfo
- Publication number
- AR108552A1 AR108552A1 ARP170101381A ARP170101381A AR108552A1 AR 108552 A1 AR108552 A1 AR 108552A1 AR P170101381 A ARP170101381 A AR P170101381A AR P170101381 A ARP170101381 A AR P170101381A AR 108552 A1 AR108552 A1 AR 108552A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapeutic agent
- value
- cells
- rate
- il2r
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 18
- 229940124597 therapeutic agent Drugs 0.000 title abstract 18
- 238000000034 method Methods 0.000 title abstract 4
- 239000000463 material Substances 0.000 title 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
En particular, se refiere a regímenes de administración para agentes terapéuticos capaces de reconocer el receptor de IL-2, preferentemente agentes terapéuticos basados en interleuquina 2 (IL-2). Los métodos permiten determinar regímenes generales de administración para agentes terapéuticos con diana en IL-2R, aunque también regímenes de administración específicamente adaptados para individuos bajo tratamiento con agentes terapéuticos con diana en IL-2R. Reivindicación 1: Método para la determinación de un régimen de administración óptimo para un agente terapéutico, comprendiendo dicho método: a) simular un modelo utilizando datos obtenidos de uno o más individuos en uno o más puntos temporales tras la administración de una dosis del agente terapéutico, en el que los datos incluyen datos FC referidos a la cantidad de agente terapéutico no unido, en el que el modelo es: en la que [Ab]ₗⁱᵇʳₑ es la concentración de agente terapéutico no unido en el plasma; [IL2R]ₗⁱᵇʳₑ es la concentración de células inmunológicas no unidas que expresan receptor de IL-2 en la sangre y dada por kⁱₙ / kₒᵘₜ. u opcionalmente obtenida a partir de datos FC; [Complejo] es la concentración del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 (células IL2R⁺); kₑₗⁱₘ. es una tasa de eliminación constante del agente terapéutico del plasma y presenta un valor de entre 0.02 y 0.04 hora⁻¹; kₒₙ es una tasa de asociación del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 y presenta un valor de entre 0.26 y 4.5 mM.⁻¹h⁻¹; kₒᶠᶠ es la tasa de disociación del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 y presenta un valor de entre 0.0035 y 0.02 h⁻¹; kⁱₙ es la tasa de flujo de entrada constante de células IL2R⁺ en el plasma y presenta un valor de entre 0.0006 y 0.0144 mM.h⁻¹; kₒᵘₜ es la tasa de descomposición natural de las células IL2R⁺ en el plasma y presenta un valor de entre 0.0018 y 0.069 h⁻¹; kⁱₙₜ es la tasa de internalización del agente terapéutico y presenta un valor de entre 0.0066 y 0.023 h⁻¹; y h es la tasa constante de expansión de las células IL2R⁺ en el plasma como resultado de la unión (internalización) del agente terapéutico y presenta un valor de entre 1.02 y 3.31, b) proporciona un régimen de administración óptimo basado en el incremento de agente terapéutico necesario para compensar la reducción de agente terapéutico libre, en el que agente terapéutico es un compuesto que es capaz de reconocer IL2R.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171263 | 2016-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108552A1 true AR108552A1 (es) | 2018-08-29 |
Family
ID=56096950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101381A AR108552A1 (es) | 2016-05-25 | 2017-05-23 | Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12094586B2 (es) |
| EP (1) | EP3465494A1 (es) |
| JP (1) | JP6943885B2 (es) |
| KR (1) | KR20190015345A (es) |
| CN (1) | CN109478421B (es) |
| AR (1) | AR108552A1 (es) |
| AU (1) | AU2017269764A1 (es) |
| BR (1) | BR112018074152A8 (es) |
| CA (1) | CA3025050A1 (es) |
| IL (1) | IL263073A (es) |
| MX (1) | MX2018014432A (es) |
| WO (1) | WO2017202786A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | ＭＡｄＣＡＭ標的化免疫寛容 |
| US20220370563A1 (en) * | 2019-10-25 | 2022-11-24 | Neoleukin Therapeutics, Inc. | Methods of administration of il-2 receptor agonists |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10245508A1 (de) * | 2002-09-27 | 2004-04-08 | Mcs Micro Carrier Systems Gmbh | Medikament-Dosimeter-Kombipackung |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| ES2529211T3 (es) | 2005-11-29 | 2015-02-18 | Children's Hospital Medical Center | Optimización e individualización de la selección y dosificación de medicamentos |
| DE102006028232A1 (de) * | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
| EP4332839A3 (en) * | 2013-12-06 | 2024-06-05 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| EP3193915A1 (en) * | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| EP3482766B1 (en) * | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2017
- 2017-05-22 WO PCT/EP2017/062302 patent/WO2017202786A1/en unknown
- 2017-05-22 AU AU2017269764A patent/AU2017269764A1/en not_active Abandoned
- 2017-05-22 MX MX2018014432A patent/MX2018014432A/es unknown
- 2017-05-22 BR BR112018074152A patent/BR112018074152A8/pt not_active IP Right Cessation
- 2017-05-22 KR KR1020187037309A patent/KR20190015345A/ko active IP Right Grant
- 2017-05-22 CA CA3025050A patent/CA3025050A1/en not_active Abandoned
- 2017-05-22 EP EP17727144.2A patent/EP3465494A1/en active Pending
- 2017-05-22 JP JP2018561513A patent/JP6943885B2/ja active Active
- 2017-05-22 CN CN201780045896.7A patent/CN109478421B/zh active Active
- 2017-05-23 AR ARP170101381A patent/AR108552A1/es unknown
-
2018
- 2018-11-18 IL IL263073A patent/IL263073A/en unknown
- 2018-11-20 US US16/196,883 patent/US12094586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014432A (es) | 2019-04-01 |
| BR112018074152A2 (pt) | 2019-03-06 |
| WO2017202786A1 (en) | 2017-11-30 |
| US12094586B2 (en) | 2024-09-17 |
| CN109478421B (zh) | 2024-07-09 |
| IL263073A (en) | 2019-03-31 |
| BR112018074152A8 (pt) | 2023-01-31 |
| US20190361018A1 (en) | 2019-11-28 |
| JP6943885B2 (ja) | 2021-10-06 |
| AU2017269764A1 (en) | 2018-12-13 |
| JP2019530907A (ja) | 2019-10-24 |
| CN109478421A (zh) | 2019-03-15 |
| EP3465494A1 (en) | 2019-04-10 |
| CA3025050A1 (en) | 2017-11-30 |
| KR20190015345A (ko) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108552A1 (es) | Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos | |
| CO2019010698A2 (es) | Vacunas de peptidos | |
| CL2018002763A1 (es) | Moléculas de unión a bcma y métodos de uso de las mismas. | |
| MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
| CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
| PH12018502250A1 (en) | Cancer immunotherapy by immune activation for immune modulation via globo series antigens | |
| EA202190295A1 (ru) | Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии | |
| MX2021006238A (es) | Metodos para tratamiento que usan terapia celular adoptiva. | |
| EA201991692A1 (ru) | Иммуносконструированные плюрипотентные клетки | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| MX2019015155A (es) | Modelo de raton para valorar toxicidades asociadas con inmunoterapias. | |
| AR104296A1 (es) | Infusión arterial hepática de células car-t | |
| NI202100064A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| WO2008094178A3 (en) | Models for vaccine assessment | |
| MX2021006393A (es) | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. | |
| AR066306A1 (es) | Conjunto de partes para el tratamiento del cancer o enfermedades infecciosas. composicion farmaceutica- usos | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| EA201892443A1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| CL2021000532A1 (es) | Vacunas peptídicas | |
| WO2019113375A3 (en) | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |